130
Participants
Start Date
September 5, 2018
Primary Completion Date
July 25, 2024
Study Completion Date
November 30, 2025
IMNN-001
IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
Carboplatin
AUC 6 IV over 1 hour on Day 1 of each cycle
Paclitaxel
175 mg/m2 IV over 3 hours on Day 1 of each cycle
NYU Langone, New York
Monter Cancer Center, Lake Success
NYU Langone, Long Island, Mineola
Advent Health, Orlando
Women's Care Florida, St. Petersburg
University of Alabama Birmingham, Birmingham
Mitchell Cancer Institute (University of South Alabama), Mobile
Chattanooga Women's Health, Chattanooga
The West Clinic, Germantown
Medical College of Wisconsin, Milwaukee
Sanford Health, Sioux Falls
Washington University School of Medicine in St. Louis, St Louis
Stephenson Cancer Center - Oklahoma University, Oklahoma City
Innovative Clinical Research, Whittier
Gynecologic Oncology Associates (Hoag Hospital), Newport Beach
Providence Cancer Institute, Portland
Providence Health Care, Spokane
Massachusetts General Hospital, Boston
MD Anderson at Cooper, Camden
Hackensack University Medical Center, Hackensack
CHUM, Montreal
Lead Sponsor
Imunon
INDUSTRY